Search
antineoplastic agent (chemotherapeutic agent)
Adverse effects:
- nearly all chemotherapeutic agents are associated with urticaria & morbilliform rash [1]
Notes:
- manufacturers have total price control of cancer drugs
- DrugAbacus can help physicians calculate what a cancer drug should cost
- ASCO proposed experiments in outcomes-based pricing of cancer drugs [2]
Related
chemotherapy
Specific
1-(2-choloroethyl)-3-(2,5-dioxo-3-piperidyl)-1-nitrosourea (PCNU)
2-chlorodeoxyadenosine (2-CdA) [cladribine] (Leustatin)
5-fluorouracil [5-FU] (Fluoroplex, Efudex, Adrucel, Carac)
6-mercaptopurine (Purinethol, 6-MP, Mecaleukin, Leukerin, Leupurin)
abarelix (Plenaxis)
abiraterone acetate (Zytiga)
alitretinoin (Panretin)
alkylating agent
alkylating agent combination
all-trans retinoic acid; tretinoin (Retin-A, Renova, Avita, Altreno, ATRA)
amcenestrant
antibiotic antineoplastic agent
antimitotic agent; mitotic inhibitor (antineoplastic agent)
antineoplastic combination (combination chemotherapy)
antineoplastic endocrine agent
antineoplastic enzyme inhibitor
antineoplastic immunomodulator
antineoplastic monoclonal antibody
antineoplastic photosensitizing agent
antineoplastic platinum complex; platinum-based chemotherapy
antineoplastic tyrosine kinase inhibitor
antineoplastic-adjuvant combination
antineoplaton
apalutamide (Erleada)
arsenic trioxide; As2O3 (Trisenox)
asparaginase (Elspar)
azacitidine; 5-azacytidine (Vidaza, Onureg)
Bacillus Calmette-Guerin (BCG, TheraCys, TICE, Pacis)
belagenpumatucel-L (Lucanix)
belinostat (Beleodaq)
belzutifan (Welireg)
bexarotene (Targretin)
BMS-354825
brentuximab vedotin (Adcetris)
buserelin (Suprecur)
cabazitaxel
calaspargase pegol-mkn (Asparlas)
capecitabine (Xeloda)
cedazuridine
cepharanthine
checkpoint inhibitor; immune checkpoint inhibitor; PD-1/PD-L1 inhibitor
clofarabine (Clolar)
CMP-001
cytosine arabinoside; cytarabine (Cytosar, ARA-C, HiDAC, Depocyt)
decitabine or 5-aza-2'-deoxycytidine
dordaviprone (Modeyso, ONC201)
enzalutamide (Xtandi)
epothilone
eribulin mesylate (Halaven)
flavopiridol
floxuridine; fluorodeoxyurine; 2'-Deoxy-5-fluorouridine
fludarabine (Fludara)
GDC-0449
gemcitabine (Gemzar)
gilteritinib (Xospata)
gp100:209-217(210 M) peptide vaccine
idecabtagene vicleucel (Abecma)
imetelstat (Rytelo)
imlunestrant (Inluriyo)
levamisole (Ergamisole)
metyrosine (Demser)
midostaurin (Rydapt)
mifamurtide (Mepact)
mitomycin C (Mutamycin, Mitomycinum, Ametycin, Zusduri)
mitoxantrone (Novantrone, Mitozantrone)
mycophenolate (Cellcept, Myfortic)
nadofaragene firadenovec
nelarabine (Arranon)
nimustine (ACNU)
nirogacestat (Ogsiveo)
nocodazole
nogapendekin alfa inbakicept-pmln (Anktiva)
oblimersen (Bcl-2 antisense)
omacetaxine mepesuccinate; homoharringtonine (Synribo)
panobinostat (Farydak)
pegaspargase (Oncaspar, PEG-L-asparaginase)
pentostatin (Nipent, DCF, 2'deoxycoformycin)
plerixafor (Mozobil)
Polatuzumab Vedotin (POLIVY)
pralatrexate (Folotyn)
proxigermanium; propagermanium; Ge-132- carboxyethylgermanium sesquioxide; 2-carboxyethylgermasesquioxane
rabacfosadine (Tanovea)
radium Ra[223] dichloride (Xofigo)
radium-223
raltitrexed (Tomudex)
ramucirumab (Cyramza)
ricin
salinomycin; salinomycinum (Coxistac)
samarium [Sm-153] lexidronam
sintilimab
small inhibitory antineoplastic agent (ib drug)
strontium chloride
tafasitamab-cxix (Monjuvi)
tagraxofusp (Elzonris)
talimogene laherparepvec (Imlygic)
tazemetostat (Taxverik)
tebentafusp-tebn (Kimmtrak)
testolactone (Teslac, Fludestrin)
TG101348
tipiracil
tirapazamine (TPZ)
tirbanibulin (Klisyri)
tisagenlecleucel; CTL019 (Kymriah)
topoisomerase inhibitor
trabectedin (Yondelis)
treosulfan (Grafapex)
venetoclax (Venclexta)
verdinexor (Laverdia-CA1)
General
pharmaceutical agent
Properties
References
- Medical Knowledge Self Assessment Program (MKSAP) 16
American College of Physicians, Philadelphia 2012
- American Society of Clinical Oncology (ASCO) Position Statement
On Addressing the Affordability of Cancer Drugs.
June 1, 2017
http://www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/documents/2017-ASCO-Position-Statement-Affordability-Cancer-Drugs.pdf
Component-of
antineoplastic-adjuvant combination